301 related articles for article (PubMed ID: 7904088)
21. Protective effect of encapsulated cells producing neurotrophic factor CNTF in a monkey model of Huntington's disease.
Emerich DF; Winn SR; Hantraye PM; Peschanski M; Chen EY; Chu Y; McDermott P; Baetge EE; Kordower JH
Nature; 1997 Mar; 386(6623):395-9. PubMed ID: 9121555
[TBL] [Abstract][Full Text] [Related]
22. Dopamine D3 receptor is decreased and D2 receptor is elevated in the striatum of Parkinson's disease.
Ryoo HL; Pierrotti D; Joyce JN
Mov Disord; 1998 Sep; 13(5):788-97. PubMed ID: 9756147
[TBL] [Abstract][Full Text] [Related]
23. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
24. Detailed mapping of the histamine H2 receptor and its gene transcripts in guinea-pig brain.
Vizuete ML; Traiffort E; Bouthenet ML; Ruat M; Souil E; Tardivel-Lacombe J; Schwartz JC
Neuroscience; 1997 Sep; 80(2):321-43. PubMed ID: 9284338
[TBL] [Abstract][Full Text] [Related]
25. Neurotransmitter receptor alterations in Huntington's disease: autoradiographic and homogenate studies with special reference to benzodiazepine receptor complexes.
Whitehouse PJ; Trifiletti RR; Jones BE; Folstein S; Price DL; Snyder SH; Kuhar MJ
Ann Neurol; 1985 Aug; 18(2):202-10. PubMed ID: 2994554
[TBL] [Abstract][Full Text] [Related]
26. Dopamine D1 and D2 receptor gene expression in the striatum in Huntington's disease.
Augood SJ; Faull RL; Emson PC
Ann Neurol; 1997 Aug; 42(2):215-21. PubMed ID: 9266732
[TBL] [Abstract][Full Text] [Related]
27. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers.
Suzuki M; Desmond TJ; Albin RL; Frey KA
Synapse; 2001 Sep; 41(4):329-36. PubMed ID: 11494403
[TBL] [Abstract][Full Text] [Related]
28. Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases.
Goodchild RE; Court JA; Hobson I; Piggott MA; Perry RH; Ince P; Jaros E; Perry EK
Eur J Neurosci; 1999 Feb; 11(2):449-56. PubMed ID: 10051746
[TBL] [Abstract][Full Text] [Related]
29. A morphometric reevaluation of Huntington's chorea with special reference to the large neurons in the neostriatum.
Oyanagi K; Ikuta F
Clin Neuropathol; 1987; 6(2):71-9. PubMed ID: 2954733
[TBL] [Abstract][Full Text] [Related]
30. Second messenger systems in brains of patients with Parkinson's or Huntington's disease.
Tanaka C; Nishino N; Hashimoto T; Kitamura N; Yoshihara C; Saito N
Adv Neurol; 1993; 60():175-80. PubMed ID: 8093576
[TBL] [Abstract][Full Text] [Related]
31. Influences of dopaminergic lesion on epidermal growth factor-ErbB signals in Parkinson's disease and its model: neurotrophic implication in nigrostriatal neurons.
Iwakura Y; Piao YS; Mizuno M; Takei N; Kakita A; Takahashi H; Nawa H
J Neurochem; 2005 May; 93(4):974-83. PubMed ID: 15857400
[TBL] [Abstract][Full Text] [Related]
32. Susceptibility of striatal neurons to excitotoxic injury correlates with basal levels of Bcl-2 and the induction of P53 and c-Myc immunoreactivity.
Liang ZQ; Wang XX; Wang Y; Chuang DM; DiFiglia M; Chase TN; Qin ZH
Neurobiol Dis; 2005 Nov; 20(2):562-73. PubMed ID: 15922606
[TBL] [Abstract][Full Text] [Related]
33. Mesostriatal and mesolimbic dopamine uptake binding sites are reduced in Parkinson's disease and progressive supranuclear palsy: a quantitative autoradiographic study using [3H]mazindol.
Chinaglia G; Alvarez FJ; Probst A; Palacios JM
Neuroscience; 1992 Jul; 49(2):317-27. PubMed ID: 1436470
[TBL] [Abstract][Full Text] [Related]
34. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia.
Albin RL; Reiner A; Anderson KD; Penney JB; Young AB
Ann Neurol; 1990 Apr; 27(4):357-65. PubMed ID: 1972318
[TBL] [Abstract][Full Text] [Related]
35. Pharmacological characterization and autoradiographic localization of histamine H2 receptors in human brain identified with [125I]iodoaminopotentidine.
Traiffort E; Pollard H; Moreau J; Ruat M; Schwartz JC; Martinez-Mir MI; Palacios JM
J Neurochem; 1992 Jul; 59(1):290-9. PubMed ID: 1351926
[TBL] [Abstract][Full Text] [Related]
36. Striatal modulation of cAMP-response-element-binding protein (CREB) after excitotoxic lesions: implications with neuronal vulnerability in Huntington's disease.
Giampà C; DeMarch Z; D'Angelo V; Morello M; Martorana A; Sancesario G; Bernardi G; Fusco FR
Eur J Neurosci; 2006 Jan; 23(1):11-20. PubMed ID: 16420411
[TBL] [Abstract][Full Text] [Related]
37. Reduced expression of preproenkephalin in striatal neurons from Huntington's disease patients.
Richfield EK; Maguire-Zeiss KA; Cox C; Gilmore J; Voorn P
Ann Neurol; 1995 Mar; 37(3):335-43. PubMed ID: 7695232
[TBL] [Abstract][Full Text] [Related]
38. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
Calon F; Dridi M; Hornykiewicz O; Bédard PJ; Rajput AH; Di Paolo T
Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896
[TBL] [Abstract][Full Text] [Related]
39. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia.
Silverdale MA; Crossman AR; Brotchie JM
Exp Neurol; 2002 Mar; 174(1):21-8. PubMed ID: 11869030
[TBL] [Abstract][Full Text] [Related]
40. Striatal interneurons in Huntington's disease: selective increase in the density of calretinin-immunoreactive medium-sized neurons.
Cicchetti F; Parent A
Mov Disord; 1996 Nov; 11(6):619-26. PubMed ID: 8914086
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
